NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000 , meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking ...
Show more
See More
NeoChord has raised a total of $89.9M in funding over 13 rounds. Their latest funding was raised on May 6, 2021 from a Convertible Note round. NeoChord is funded by 10 investors. Treo Ventures and U.S. Venture Partners are the most recent investors. NeoChord has a post-money valuation in the range of $100M to $500M as of Aug 6, 2020, according to PrivCo. Sign up for …
Founder: John Seaberg
Location: Saint Louis Park, Minnesota
Founded: Jul 01, 2007
Show more
See More
Based in Minneapolis, MN, NeoChord is a small health care company with only 30 employees and an annual revenue of $1.6M. The Organization’s Mission. To obtain the predicted probability of presenting MR less or equal to mild at follow-up, locate patient echocardiographic values at each axis. Industry. Health Care.
Employees: 30
Show more
See More
NeoChord NeXuS is an investigational device and is not commercially available. Contact Jenny Donovan NeoChord, Inc. (952) 698-7809 jdonovan@NeoChord.com ...
Show more
See More
Aug 14, 2018 . The NeoChord device, in illustration, is inserted in the beating heart through a small incision, guided by echocardiography “While the heart is beating, you make a small incision under the patient’s left nipple, insert the device, and implant the artificial chords to the mitral valve,” says Dr. El-Eshmawi, the site Principal Investigator for the study.
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
Jan 08, 2013 . NeoChord also announced that it has already started a clinical study, known as the Transapical Artificial Chordae Tendinae (TACT) study. The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year.
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
Oct 16, 2009 . Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
Nov 04, 2018 . The NeoChord transcatheter mitral repair procedure is performed in a standard cardiac operating theatre suite. Optimal 2D- and 3D-TEE imaging units are mandatory for procedural navigation and real-time assessment of mitral regurgitation. The patient is placed under general anesthesia with single-lung ventilation, and positioned supine with a 30 ...
Show more
See More
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation.
Show more
See More
prefer using the loop NeoChord technique for most patients with MV prolapse.7-9 A variety of approaches to expose the MV have been described, including minimally invasive approaches with an array of cannulation strategies for cardiopulmonary bypass.8,10-12 The advantages and disadvantages of mini-
Show more
See More
ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients ...
Show more
See More
NeoChord, Inc., a Minneapolis-based medical technology start-up, obtained an exclusive license for D. Speziali’s technology and partnered with Worrell to develop the device. Worrell’s researchers began by conducting an operative immersion, documenting preliminary feedback from surgeons performing similar procedures on animal specimens.
Show more
See More
NeoChord $74.74 m in total funding,. See insights on NeoChord including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
Show more
See More
The NeoChord System: Artificial Muscles Support the Valve. The NeoChord System uses artificial muscles to repair this defect. These cords can be applied without the use of a heartlung machine. They are placed on the diseased portion of the mitral valve through a small incision in the chest. A national trial of this device will begin in early ...
Show more
See More
NeoChord General Information Description. Developer of a mitral valve repair tool designed to restore mitral valve function for patients suffering from severe mitral regurgitation due to leaflet prolapse. The company's tool is used for conducting a minimally invasive procedure when the native chordae tendinae have become elongated or ruptured ...
Show more
See More
Mitral valve repair using the NeoChord technique is equivalent to replacement of the damaged filaments with new artificial cords made of Gore-Tex - approx. one millimetre thick and from 5 to 7 cm long - applied under the valve with a suture model similar to the sartorial stitches made by a sewing machine.
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year. Dr. Giovanni Speziali, one of the proctors of the study from the University of Pittsburgh Medical Center, stated:
A clinical study is ongoing within the United States to evaluate the use of the NeoChord DS1000. Mount Sinai Heart is leading a multicenter clinical trial of a minimally invasive mitral valve prolapse repair technology that has the potential to transform the standard of care for the disorder.